Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912287717> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2912287717 endingPage "194" @default.
- W2912287717 startingPage "191" @default.
- W2912287717 abstract "Lung adenocarcinoma, the most widespread cause of neoplasm associated mortality in both men and women worldwide, is a subtype of non-small cell lung cancer (NSCLC). We address here the case of a 62-year-old female presented with symptoms of cough and breathlessness of 2-months duration. Histopathological examination of lung biopsy and immunohistochemical tests revealed lung adenocarcinoma. Integrated positron emission tomography-computed tomography (PET-CT) scan suggested right lung lesion with stage 4 (T3N3M1b) disease. Epidermal growth factor receptor (EGFR) mutation analysis was positive for exon-19 deletion mutation, and she was started on afatinib 40 mg once daily. PET-CT scan, at 6-months follow-up, was suggestive of complete response to therapy. Due to drug-induced persistent diarrhea, afatinib was discontinued by the patient, but a repeat PET-CT scan 6 months after discontinuation of treatment suggested disease recurrence. However, T790M-resistant mutation analysis was found to be negative, and she was restarted on afatinib at 30 mg once daily to minimize the drug-related diarrhea. After 15 months of afatinib therapy at reduced dosage, reevaluation by PET-CT suggested disease progression. Although afatinib monotherapy is effective in EGFR exon-19 deletion mutation NSCLC, this report suggests that discontinuation of the drug can lead to disease recurrence, and reducing the drug dose is not beneficial once disease recurrence occurs. To the best of our knowledge, this is the first reported case from India of advanced lung adenocarcinoma of EGFR exon-19 deletion showing a complete response to afatinib and recurrence of the disease after discontinuation of drug." @default.
- W2912287717 created "2019-02-21" @default.
- W2912287717 creator A5013231122 @default.
- W2912287717 creator A5035846372 @default.
- W2912287717 creator A5065385001 @default.
- W2912287717 date "2018-12-01" @default.
- W2912287717 modified "2023-09-27" @default.
- W2912287717 title "Complete Response to Afatinib in Lung Adenocarcinoma of Epidermal Growth Factor Receptor Exon-19 Deletion Mutation and Disease Recurrence on Drug Discontinuation" @default.
- W2912287717 doi "https://doi.org/10.4103/jpp.jpp_111_18" @default.
- W2912287717 hasPublicationYear "2018" @default.
- W2912287717 type Work @default.
- W2912287717 sameAs 2912287717 @default.
- W2912287717 citedByCount "1" @default.
- W2912287717 countsByYear W29122877172019 @default.
- W2912287717 crossrefType "journal-article" @default.
- W2912287717 hasAuthorship W2912287717A5013231122 @default.
- W2912287717 hasAuthorship W2912287717A5035846372 @default.
- W2912287717 hasAuthorship W2912287717A5065385001 @default.
- W2912287717 hasBestOaLocation W29122877171 @default.
- W2912287717 hasConcept C104317684 @default.
- W2912287717 hasConcept C121608353 @default.
- W2912287717 hasConcept C126322002 @default.
- W2912287717 hasConcept C143998085 @default.
- W2912287717 hasConcept C170493617 @default.
- W2912287717 hasConcept C2776256026 @default.
- W2912287717 hasConcept C2778087573 @default.
- W2912287717 hasConcept C2778715236 @default.
- W2912287717 hasConcept C2779134260 @default.
- W2912287717 hasConcept C2779438470 @default.
- W2912287717 hasConcept C2780035454 @default.
- W2912287717 hasConcept C2780586478 @default.
- W2912287717 hasConcept C2781182431 @default.
- W2912287717 hasConcept C36823959 @default.
- W2912287717 hasConcept C501734568 @default.
- W2912287717 hasConcept C502942594 @default.
- W2912287717 hasConcept C54355233 @default.
- W2912287717 hasConcept C71924100 @default.
- W2912287717 hasConcept C86803240 @default.
- W2912287717 hasConcept C98274493 @default.
- W2912287717 hasConceptScore W2912287717C104317684 @default.
- W2912287717 hasConceptScore W2912287717C121608353 @default.
- W2912287717 hasConceptScore W2912287717C126322002 @default.
- W2912287717 hasConceptScore W2912287717C143998085 @default.
- W2912287717 hasConceptScore W2912287717C170493617 @default.
- W2912287717 hasConceptScore W2912287717C2776256026 @default.
- W2912287717 hasConceptScore W2912287717C2778087573 @default.
- W2912287717 hasConceptScore W2912287717C2778715236 @default.
- W2912287717 hasConceptScore W2912287717C2779134260 @default.
- W2912287717 hasConceptScore W2912287717C2779438470 @default.
- W2912287717 hasConceptScore W2912287717C2780035454 @default.
- W2912287717 hasConceptScore W2912287717C2780586478 @default.
- W2912287717 hasConceptScore W2912287717C2781182431 @default.
- W2912287717 hasConceptScore W2912287717C36823959 @default.
- W2912287717 hasConceptScore W2912287717C501734568 @default.
- W2912287717 hasConceptScore W2912287717C502942594 @default.
- W2912287717 hasConceptScore W2912287717C54355233 @default.
- W2912287717 hasConceptScore W2912287717C71924100 @default.
- W2912287717 hasConceptScore W2912287717C86803240 @default.
- W2912287717 hasConceptScore W2912287717C98274493 @default.
- W2912287717 hasIssue "4" @default.
- W2912287717 hasLocation W29122877171 @default.
- W2912287717 hasOpenAccess W2912287717 @default.
- W2912287717 hasPrimaryLocation W29122877171 @default.
- W2912287717 hasRelatedWork W2060452880 @default.
- W2912287717 hasRelatedWork W2350207578 @default.
- W2912287717 hasRelatedWork W2366356213 @default.
- W2912287717 hasRelatedWork W2772338590 @default.
- W2912287717 hasRelatedWork W2908307873 @default.
- W2912287717 hasRelatedWork W3036162643 @default.
- W2912287717 hasRelatedWork W4224237029 @default.
- W2912287717 hasRelatedWork W4306643401 @default.
- W2912287717 hasRelatedWork W4362611067 @default.
- W2912287717 hasRelatedWork W4362621128 @default.
- W2912287717 hasVolume "9" @default.
- W2912287717 isParatext "false" @default.
- W2912287717 isRetracted "false" @default.
- W2912287717 magId "2912287717" @default.
- W2912287717 workType "article" @default.